The Bill & Melinda Gates Foundation has committed $40 million in equity investment and $10 million in grant funding to Vir Biotechnology for the development of therapies against HIV and Malaria, Vir announced Friday. Read the full Press Release here.
Inventprise is an innovative vaccine development company based out of Redmond, Washington that is focused on developing efficacious, affordable vaccines for global populations most in need. The foundation invested in the Company to advance its novel pneumococcal conjugate vaccine (“IVT-25”). Read More
[September 8, 2021] Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, today announced a four-year collaboration with the Bill & Melinda Gates Foundation, a non-profit focused on fighting global poverty, disease, and inequity, Read More
Exscientia plc is an artificial intelligence-driven pharmaceutical company focused on discovering, designing, and developing drugs in a fast, efficient manner, with three AI-designed drugs that are in Phase 1 human clinical trials. The foundation invested in the Company to develop Read More
XCONOMY SAN FRANCISCO – Vir Biotechnology has joined the public markets, raising $142.9 million to support clinical tests of its infectious disease drugs. Read the full press release here.
University of California, Davis Study Shows up to 98% Reduction of Intestinal Inflammation Markers Linked to Colic, Eczema, Asthma and Diabetes DAVIS, Calif., Sept. 10, 2019 /PRNewswire/ — Findings from a new study published today in Pediatric Research show that feeding activated Read More
Breakthrough Study Reveals Activated B. infantis EVC001 as the First Infant Probiotic to Be Effective in the Fight Against Global Health Epidemic DAVIS, Calif., Aug. 14, 2019 /PRNewswire/ — Evolve BioSystems, Inc. today announced findings from a new study that identified Read More
Significant portion of proceeds will be reinvested in neglected disease research and control efforts, fully realizing the original intent of this important public health funding mechanism Melbourne, Australia, 9 August 2019 – Today, in conjunction with its second quarter financial Read More
Atreca is a biotechnology company that employs its proprietary discovery platform to generate and develop therapeutics based on its ability to rapidly characterize the human adaptive immune response at the single cell level. The Atreca platform enables the high-throughput phylogenetic Read More
May 24, 2019 Atreca, a preclinical biotech developing immunotherapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The Redwood City, CA-based company was founded in 2010 and plans Read More